NEW YORK (GenomeWeb News) – Quest Diagnostics completed the sale of its HemoCue diagnostics product business to Danaher company Radiometer for about $300 million. The deal was originally announced in February as part of Quest's plans to divest certain non-core assets to focus on its diagnostic information services business. Quest will use proceeds from the sale to repurchase about $300 million of its shares as part of a buyback program, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."